NEW YORK (GenomeWeb News) – Signal Genetics today said that it will use its MyPRS genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.
According to the New York-based firm, it will provide Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array drug candidate. It said that the collaboration may lead to the development of "superior and personalized treatment options for myeloma patients."